Mihael H. Polymeropoulos - 05 Dec 2022 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Role
President and CEO, Director, Chairman of the Board
Signature
/s/ Mihael Polymeropoulos
Issuer symbol
VNDA
Transactions as of
05 Dec 2022
Net transactions value
-$550,282
Form type
4
Filing time
07 Dec 2022, 16:58:18 UTC
Previous filing
02 Mar 2022
Next filing
21 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VNDA Common Stock Options Exercise $232,861 +74,635 +5.5% $3.12 1,427,401 05 Dec 2022 Direct
transaction VNDA Common Stock Sale $506,200 -47,650 -3.3% $10.62 1,379,751 05 Dec 2022 Direct F1, F2
transaction VNDA Common Stock Options Exercise $235,139 +75,365 +5.5% $3.12 1,455,116 06 Dec 2022 Direct
transaction VNDA Common Stock Sale $512,082 -48,250 -3.3% $10.61 1,406,866 06 Dec 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VNDA Stock Option (Right to Buy) Options Exercise $0 -74,635 -50% $0.000000 75,365 05 Dec 2022 Common Stock 74,635 $3.12 Direct F4
transaction VNDA Stock Option (Right to Buy) Options Exercise $0 -75,365 -100% $0.000000* 0 06 Dec 2022 Common Stock 75,635 $3.12 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 6, 2022 as reflected in this Form 4.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.43 to $10.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.39 to $10.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
F4 This option fully vested and exercisable.